Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · IEX Real-Time Price · USD
4.850
+0.065 (1.36%)
Apr 16, 2024, 2:10 PM EDT - Market open
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 20, with a low estimate of 15 and a high estimate of 25. The average target predicts an increase of 312.37% from the current stock price of 4.85.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ZVRA stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +209.28% | Apr 3, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 1, 2024 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +209.28% | Mar 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +209.28% | Dec 28, 2023 |
Financial Forecast
Revenue This Year
29.92M
from 27.46M
Increased by 8.97%
Revenue Next Year
92.51M
from 29.92M
Increased by 209.15%
EPS This Year
-1.58
from -1.30
EPS Next Year
-0.47
from -1.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 45.0M | 148.4M | 241.1M | 307.2M | 473.8M |
| Avg | 29.9M | 92.5M | 161.9M | 229.9M | 307.9M |
| Low | 22.3M | 66.5M | 110.4M | 162.8M | 210.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 64.0% | 395.8% | 160.7% | 89.8% | 106.0% |
| Avg | 9.0% | 209.2% | 75.0% | 42.0% | 33.9% |
| Low | -19.0% | 122.2% | 19.3% | 0.6% | -8.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.17 | 0.51 | 1.63 | 2.92 | 3.42 |
| Avg | -1.58 | -0.47 | 0.50 | 1.87 | 2.90 |
| Low | -1.76 | -1.00 | -0.25 | 1.19 | 2.19 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 479.3% | 82.6% |
| Avg | - | - | - | 272.0% | 54.8% |
| Low | - | - | - | 135.3% | 16.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.